NATCO Pharma Limited (BOM:524816)
839.85
+15.80 (1.92%)
At close: Jan 21, 2026
NATCO Pharma Revenue
NATCO Pharma had revenue of 13.63B INR in the quarter ending September 30, 2025, a decrease of -0.59%. This brings the company's revenue in the last twelve months to 43.90B, down -3.81% year-over-year. In the fiscal year ending March 31, 2025, NATCO Pharma had annual revenue of 44.32B with 10.74% growth.
Revenue (ttm)
43.90B
Revenue Growth
-3.81%
P/S Ratio
3.39
Revenue / Employee
10.46M
Employees
4,199
Market Cap
149.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.32B | 4.30B | 10.74% |
| Mar 31, 2024 | 40.02B | 12.94B | 47.76% |
| Mar 31, 2023 | 27.09B | 7.62B | 39.17% |
| Mar 31, 2022 | 19.46B | -1.10B | -5.35% |
| Mar 31, 2021 | 20.56B | 1.41B | 7.37% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |
NATCO Pharma News
- 14 days ago - Pharma sector stocks today: Natco Pharma jumps 1.24%, Dr. Reddy’s Lab gain 0.32%, Divi’s Laboratories up 0.14% - Business Upturn
- 7 weeks ago - Natco Pharma shares rise over 4% as expansion strategy boosts investor sentiment - Business Upturn
- 2 months ago - NATCO Pharma concludes US FDA inspection at Chennai API unit, receives seven form 483 observations - Business Upturn
- 2 months ago - Natco Pharma Ltd (BOM:524816) Q2 2026 Earnings Call Highlights: Strategic Wins and Future ... - GuruFocus
- 2 months ago - Q2 2026 Natco Pharma Ltd Earnings Call Transcript - GuruFocus
- 2 months ago - NATCO Pharma Q2 Results: Net profit drops 23% YoY to Rs 518 crore, revenue flat at Rs 1,363 crore - Business Upturn
- 3 months ago - NATCO Pharma launches Generic Everolimus Tablets 1mg in the U.S. market - Business Upturn
- 3 months ago - Pharma expansion: Natco to acquire major stake in South Africa’s Adcock Ingram, firm to go private - The Times of India